| OPINION |
|
| Year : 2022 | Volume
: 13
| Issue : 3 | Page : 129-131 |
|
|
Need for revision: EC process, members' training, and compensation formula in the New Drugs and Clinical Trials Rules 2019
Ravindra Bhaskar Ghooi
Scientia Clinical Services, Pune, Maharashtra, India
Correspondence Address:
Dr. Ravindra Bhaskar Ghooi
E 516, The Island, Wakad, Pune - 411 057, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/picr.picr_251_21
|
|
|
The New Drugs and Clinical Trial Rules (NDCTR) came in force in 2019, these brought in some changes, but certain earlier parts, such as Rule 122 DAB, were incorporated unchanged. A few sections of the NDCTR are problematic and need revision for the smooth conduct of clinical trials in India. Training of Ethics Committee (EC) members and other stakeholders is a very important driver for clinical research but has not been defined clearly. In addition, some processes of EC review need a relook. Compensation formulae were finalized in 2013; now, the altered economic situation has eroded the value of money. Hence, for the protection of research participants, an urgent review of the compensation formula is suggested. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
